Verrica Pharmaceuticals announces litigation settlement with Dormer Labs

Verrica Pharmaceuticals announced the settlement of litigation with Dormer Laboratories. As part of the settlement, Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States, including Dormer brands Cantharone and Cantharone Plus. “We are pleased to announce the expeditious settlement with Dormer Labs, which Verrica believes was the largest supplier of non-FDA approved cantharidin-containing products into the U.S. market,” said Ted White, CEO. “This settlement should send a clear message that Verrica will remain vigilant in its efforts to identify and stop any drug manufacturer or distributor that seeks to market, sell or distribute non-FDA approved cantharidin in the United States. We believe that this settlement will result in greater patient usage of the FDA-approved YCANTH. We remain vigilant regarding any U.S. based pharmacies or outsourcing facilities improperly compounding cantharidin without adhering to the requirements and parameters established by the FDA. Patient safety is imperative, and compounded cantharidin is not only unapproved, but it can be harmful to patients due to its lack of stability and inconsistent concentration. YCANTH is the only commercially available cantharidin therapy for the treatment of molluscum contagiosum that the FDA has found to be safe and effective.”